Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Newly diagnosed myeloma patients with low-burden disease may benefit from tandem autologous stem cell transplantation: results of long-term follow-up

Bone Marrow Transplantation volume 55, pages 1200–1202 (2020)Cite this article

Subjects

The introduction of high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with newly diagnosed multiple myeloma (NDMM) improved overall responses and their depth, prolonged progression-free survival (PFS), and increased overall survival (OS). ASCT has become the therapy mainstay in transplant-eligible MM patients. In the late 1990s, tandem ASCT (T-ASCT) was proposed for NDMM management [1], albeit the results of these studies were inconclusive [2,3,4].

The arrival of novel agents, including proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, has dramatically improved patient outcomes. However, while ASCT performed following induction with a combination of lenalidomide, bortezomib, and dexamethasone was shown to delay MM progression, this did not prolong OS [5].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55–65.

    Article  CAS  Google Scholar 

  2. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101:100–6.

    Article  CAS  Google Scholar 

  3. Naumann-Winter F, Greb A, Borchmann P, Bohlius J, Engert A, Schnell R. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev. 2012;10:CD004626.

    PubMed  Google Scholar 

  4. Mai EK, Benner A, Bertsch U, Brossart P, Hanel A, Kunzmann V, et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br J Haematol. 2016;173:731–41.

    Article  CAS  Google Scholar 

  5. Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.

    Article  CAS  Google Scholar 

  6. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma. J Clin Oncol. 2019;37:589–97.

  7. Cavo M, Gay FM, Patriarca F, Zamagni E, Montefusco V, Dozza L, et al. Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02/HO95 study. Blood. 2017;130:401.

    Google Scholar 

  8. Cavo M, Goldschmidt H, Rosinol L, Pantani L, Zweegman S, Salwender HJ, et al. Double vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: long-term follow-up (10-years) analysis of randomized phase 3 studies. Blood. 2018;132:124.

    Article  Google Scholar 

  9. Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma—an IMWG Research Project. Blood. Blood Cancer J. 2018;8:123.

    Article  Google Scholar 

  10. Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017;28:228–45.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to acknowledge with thanks the assistance of Sonia Kamenetsky in the preparation of the manuscript.

Author information

Author notes

  1. These authors contributed equally: Noam Benyamini, Noa Lavi

Authors and Affiliations

  1. Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Noam Benyamini

  2. Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel

    Noa Lavi, Tsila Zuckerman, Jacob M. Rowe & Tamar Katz

  3. Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

    Noa Lavi, Tsila Zuckerman, Jacob M. Rowe & Tamar Katz

  4. Hematology Unit, HaEmek Medical Center, Afula, Israel

    Ariel Aviv

  5. Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel

    Jacob M. Rowe

Authors
  1. Noam Benyamini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noa Lavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tsila Zuckerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ariel Aviv
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacob M. Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tamar Katz
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NB, NL and TK designed and performed research, interpreted results, wrote the paper and approved the final version of the paper. TZ performed research, interpreted results and approved the final version of the paper. AA performed research and approved the final version of the paper. JMR designed research, wrote the paper and approved the final version of the paper.

Corresponding author

Correspondence to Noam Benyamini.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Benyamini, N., Lavi, N., Zuckerman, T. et al. Newly diagnosed myeloma patients with low-burden disease may benefit from tandem autologous stem cell transplantation: results of long-term follow-up. Bone Marrow Transplant 55, 1200–1202 (2020). https://doi.org/10.1038/s41409-019-0671-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0671-5

Search

Advanced search

Quick links